Table 1 Patient characteristics
Characteristics | Patients |
|---|---|
Entered | 8 |
Karnofsky performance score | 90–100% |
Age (years) | Â |
   Median (range) | 65.5 years (range 53 – 73 y) |
Stage (primary diagnosis) | Â |
   I | - |
   II | 6 (75%) |
   III | - |
   IV | 1 (12.5%) |
   Not available | 1 (12.5%) |
Ductal/Lobular | 7/0 |
   Not available | 1 (12.5%) |
Grading | Â |
   1 | - |
   2 | 2 (25%) |
   3 | 5 (62.5%) |
   Not available | 1 (12.5%) |
Estrogens receptor/progesteron receptor positive | 7/6 |
Her2 Status positive/negative (IHC/FISH*) | 0/8 |
Adjuvant chemotherapy | 3 (37.5%) |
Adjuvant endocrine therapy | 3 (37.5%) |
Palliative endocrine therapy | 4 (50%) |
Prior anthracycline exposure | 5 (62.5%) |
Prior capecitabine exposure | 2 (25%) |
Time to recurrence | Â |
   Median (range) | 87 months (13 – 148 m) |
Treatment line | Â |
   First line | 4 (50%) |
   Second line | 2 (25%) |
   >/= Third line | 2 (25%) |
Metastatic sites | Â |
   Median (range) | 2 (range 1 – 4) |
   bones/soft tissue only | 3 (37.5%) |
   visceral only | - |
   both | 5 (62.5%) |
Localisation | Â |
   Lung | 1 |
   Liver | 3 |
   Bones | 5 |
   Lymph nodes | 6 |
   Soft tissue | 2 |
   Brain | 1 |
   Skin | 1 |
More than one metastatic site | 7 (87.5%) |